Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

753
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
753
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

889
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
889
Glaucoma: Overview01:25

Glaucoma: Overview

981
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
981

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Delayed-onset cytomegalovirus retinitis after 0.2 µg/day fluocinolone acetonide implantation: a case series.

Journal of ophthalmic inflammation and infection·2026
Same author

Occlusive retinal vasculopathy on ultrawide-field fluorescein angiography in intraocular cytomegalovirus infection: a case series.

Journal of ophthalmic inflammation and infection·2026
Same author

Therapeutic vitrectomy for non-infectious uveitis.

The Cochrane database of systematic reviews·2026
Same author

Imaging Measures for the Assessment of Disease Activity in Noninfectious Posterior Uveitis - Multimodal Imaging in Uveitis (MUV) Taskforce: Report 10.

American journal of ophthalmology·2026
Same author

Intravitreal dexamethasone implant for refractory stromal choroiditis in birdshot retinochoroiditis: efficacy and therapeutic implications.

The British journal of ophthalmology·2026
Same author

International consensuses and guidelines on managing ocular Behçet's disease by the Academy of Asia-Pacific Professors of Ophthalmology (AAPPO), the Asia-Pacific Vitreo-Retina Society (APVRS), the Asia-Pacific Society of Ocular Inflammation and Infection (APSOII) and the Academia Retina Internationalis (ARI).

Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)·2025

Related Experiment Video

Updated: Oct 17, 2025

Intravitreal Injections in the Ovine Eye
03:37

Intravitreal Injections in the Ovine Eye

Published on: July 5, 2022

3.5K

Intraocular therapy in noninfectious uveitis.

Rocco Luigi Modugno1, Ilaria Testi2, Carlos Pavesio3,4

  • 1Department of Neuroscience, Ophthalmology Unit, University of Padua, Padua, Italy.

Journal of Ophthalmic Inflammation and Infection
|October 11, 2021
PubMed
Summary
This summary is machine-generated.

Local therapies offer a safer, targeted approach for non-infectious uveitis (NIU) compared to systemic treatments. This review explores options like corticosteroids, anti-VEGF agents, methotrexate, and biologics for effective NIU management.

Keywords:
Anti-tumor necrosis factor (TNF) αAnti-vascular endothelial growth factor (VEGF)BiologicsCorticosteroidsImmunosuppressive agentsIntravitrealLocal therapyMethotrexateNon-infectious uveitis

More Related Videos

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

1.1K
Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

2.9K

Related Experiment Videos

Last Updated: Oct 17, 2025

Intravitreal Injections in the Ovine Eye
03:37

Intravitreal Injections in the Ovine Eye

Published on: July 5, 2022

3.5K
Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

1.1K
Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

2.9K

Area of Science:

  • Ophthalmology
  • Immunology

Background:

  • Non-infectious uveitis (NIU) is commonly managed with systemic corticosteroids and immunosuppressants.
  • Systemic treatments carry risks, highlighting the need for localized anti-inflammatory therapies.
  • Targeting inflammation directly at the ocular site is crucial for effective and safe NIU management.

Purpose of the Study:

  • To review and analyze various local treatment options for non-infectious uveitis (NIU).
  • To evaluate the efficacy and safety profiles of different localized therapeutic modalities in NIU.

Main Methods:

  • Literature review of local treatment strategies for NIU.
  • Analysis of corticosteroids, anti-vascular endothelial growth factor (VEGF) agents, methotrexate, and biologics.
  • Assessment of treatment delivery, efficacy, and safety in the context of NIU.

Main Results:

  • Local therapies provide targeted anti-inflammatory effects for NIU.
  • Corticosteroids, anti-VEGF agents, methotrexate, and biologics represent key local treatment options.
  • The choice of local therapy depends on specific NIU characteristics and patient factors.

Conclusions:

  • Local therapy is a vital strategy in managing non-infectious uveitis (NIU).
  • Various local agents, including corticosteroids, anti-VEGF, methotrexate, and biologics, offer distinct advantages.
  • Further research into optimizing local treatment protocols for NIU is warranted.